Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.58 |
| ▸ | MMP13 | P45452 | 3/20 | 0.56 |
| ▸ | MMP2 | P08253 | 2/20 | 0.56 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29955256 | 0.84 | CREBBP (0.48) | HRH3MMP13MMP2ALDH1A1KDM4E | |
| SCHEMBL7920888 | 0.82 | ALDH1A1 (0.68) | HRH3MMP13MMP2HCRTR1ALDH1A1 | |
| SCHEMBL68923 | 0.81 | HRH3 (0.84) | HRH3MMP13MMP2HCRTR1ALDH1A1 | |
| SCHEMBL16938458 | 0.79 | HRH3 (0.59) | HRH3MMP13MMP2HCRTR1ALDH1A1 | |
| SCHEMBL29654185 | 0.79 | HRH3 (0.59) | HRH3MMP13MMP2HCRTR1ALDH1A1 | |
| SCHEMBL6518479 | 0.79 | HRH3 (0.80) | HRH3MMP13MMP2HCRTR1ALDH1A1 | |
| SCHEMBL28797830 | 0.78 | HRH3 (0.58) | HRH3MMP13MMP2HCRTR1ALDH1A1 | |
| SCHEMBL27768714 | 0.78 | HRH3 (0.58) | HRH3MMP13MMP2HCRTR1ALDH1A1 | |
| SCHEMBL27683606 | 0.78 | HRH3 (0.58) | HRH3MMP13MMP2HCRTR1ALDH1A1 | |
| SCHEMBL29654086 | 0.78 | HRH3 (0.58) | HRH3MMP13MMP2HCRTR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-1891049-B1 | METHOD FOR PRODUCING 2-(2-AMINO-PYRIMIDIN-4-YL)-1H-INDOLE-5-CARBOXYLIC ACID DERIVATIVES | SANOFI SA (FR) | 2017-07-19 | — | — | EP | disclosed |
| EP-1891049-B1 | METHOD FOR PRODUCING 2-(2-AMINO-PYRIMIDIN-4-YL)-1H-INDOLE-5-CARBOXYLIC ACID DERIVATIVES | SANOFI SA (FR) | 2017-07-19 | — | — | EP | disclosed |
| EP-2226319-B1 | Process for the preparation of 2-(2-aminopyrimidin-4-yl)-1H-indol-5-carbonic acid derivatives | SANOFI SA (FR) | 2016-03-16 | — | — | EP | disclosed |
| EP-2226319-B1 | Process for the preparation of 2-(2-aminopyrimidin-4-yl)-1H-indol-5-carbonic acid derivatives | SANOFI SA (FR) | 2016-03-16 | — | — | EP | disclosed |
| US-20140005392-A1 | METHOD FOR PRODUCING 2-(2-AMINOPYRIMIDIN-4-YL)-1H-INDOLE-5-CARBOXYLIC ACID DERIVATIVES | SANOFI (FR) | 2014-01-02 | — | — | US | disclosed |
| US-8546567-B2 | Method for producing 2-(2-aminopyrimidin-4-yl)-1H-indole-5-carboxylic acid derivatives | SANOFI (FR) | 2013-10-01 | — | — | US | disclosed |
| US-8546567-B2 | Method for producing 2-(2-aminopyrimidin-4-yl)-1H-indole-5-carboxylic acid derivatives | SANOFI (FR) | 2013-10-01 | — | — | US | disclosed |
| US-8546567-B2 | Method for producing 2-(2-aminopyrimidin-4-yl)-1H-indole-5-carboxylic acid derivatives | SANOFI (FR) | 2013-10-01 | — | — | US | disclosed |
| US-20120271051-A1 | METHOD FOR PRODUCING 2-(2-AMINOPYRIMIDIN-4-YL)-1H-INDOLE-5-CARBOXYLIC ACID DERIVATIVES | SANOFI (FR) | 2012-10-25 | — | — | US | disclosed |
| US-8232395-B2 | ethyl 2-(2-chloropyrimidin-4-yl)-1H-indole-5-carboxylate; intermediates for preparing Ikb kinase inhibitors | SANOFI (FR) | 2012-07-31 | — | — | US | disclosed |
| US-8232395-B2 | ethyl 2-(2-chloropyrimidin-4-yl)-1H-indole-5-carboxylate; intermediates for preparing Ikb kinase inhibitors | SANOFI (FR) | 2012-07-31 | — | — | US | disclosed |
| US-8232395-B2 | ethyl 2-(2-chloropyrimidin-4-yl)-1H-indole-5-carboxylate; intermediates for preparing Ikb kinase inhibitors | SANOFI (FR) | 2012-07-31 | — | — | US | disclosed |
| EP-2226319-A1 | Process for the preparation of 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonic acid derivatives | sanofi-aventis (FR) | 2010-09-08 | — | — | EP | disclosed |
| EP-2226319-A1 | Process for the preparation of 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonic acid derivatives | sanofi-aventis (FR) | 2010-09-08 | — | — | EP | disclosed |
| US-20080214813-A1 | METHOD FOR PRODUCING 2-(2-AMINOPYRIMIDIN-4-YL)-1H-INDOLE-5-CARBOXYLIC ACID DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-09-04 | — | — | US | disclosed |
| US-20080214813-A1 | METHOD FOR PRODUCING 2-(2-AMINOPYRIMIDIN-4-YL)-1H-INDOLE-5-CARBOXYLIC ACID DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-09-04 | — | — | US | disclosed |
| US-20080214813-A1 | METHOD FOR PRODUCING 2-(2-AMINOPYRIMIDIN-4-YL)-1H-INDOLE-5-CARBOXYLIC ACID DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-09-04 | — | — | US | disclosed |
| EP-1891049-A1 | METHOD FOR PRODUCING 2-(2-AMINO-PYRIMIDIN-4-YL)-1H-INDOLE-5-CARBOXYLIC ACID DERIVATIVES | Sanofi-Aventis (FR) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006128585-A1 | METHOD FOR PRODUCING 2-(2-AMINO-PYRIMIDIN-4-YL)-1H-INDOLE-5-CARBOXYLIC ACID DERIVATIVES | SANOFI-AVENTIS (DE) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120271051-A1 | METHOD FOR PRODUCING 2-(2-AMINOPYRIMIDIN-4-YL)-1H-INDOLE-5-CARBOXYLIC ACID DERIVATIVES | TPH2, IDO2, IDO1 | HRH3 708/4885MMP13 3855/4885MMP2 4096/4885 |
| US-20080214813-A1 | METHOD FOR PRODUCING 2-(2-AMINOPYRIMIDIN-4-YL)-1H-INDOLE-5-CARBOXYLIC ACID DERIVATIVES | TPH2, IDO2, IDO1 | HRH3 401/4885MMP13 3101/4885MMP2 3556/4885 |
| US-20140005392-A1 | METHOD FOR PRODUCING 2-(2-AMINOPYRIMIDIN-4-YL)-1H-INDOLE-5-CARBOXYLIC ACID DERIVATIVES | TPH2, IDO2, IDO1 | HRH3 708/4885MMP13 3855/4885MMP2 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.